Search hospitals > Washington > Spokane
Premier Clinical Research
Claim this profileSpokane, Washington 99202
Global Leader in Psoriasis
Global Leader in Acne
Conducts research for Plaque Psoriasis
Conducts research for Atopic Dermatitis
Conducts research for Eczema
116 reported clinical trials
2 medical researchers
Summary
Premier Clinical Research is a medical facility located in Spokane, Washington. This center is recognized for care of Psoriasis, Acne, Plaque Psoriasis, Atopic Dermatitis, Eczema and other specialties. Premier Clinical Research is involved with conducting 116 clinical trials across 66 conditions. There are 2 research doctors associated with this hospital, such as William Werschler and Philip Werschler.Top PIs
William WerschlerPremier Clinical Research1 year of reported clinical research
Studies Atopic Dermatitis
Studies Eczema
5 reported clinical trials
6 drugs studied
Philip WerschlerPremier Clinical Research1 year of reported clinical research
Studies Plaque Psoriasis
Studies Psoriasis
1 reported clinical trial
1 drug studied
Clinical Trials running at Premier Clinical Research
Psoriasis
Plaque Psoriasis
Hidradenitis Suppurativa
Vitiligo
Atopic Dermatitis
Eczema
Alopecia
Alopecia Areata
Male Pattern Baldness
Prurigo
Risankizumab vs Deucravacitinib
for Psoriasis
Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly. This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day 1) and who have not previously been treated with a biologic treatment (natural substance that is made by using living cells in a laboratory). This is a Phase 4, randomized, open-label, assessor blinded, active comparator study with 2 Parts. Phase 4 studies test treatments that have already been approved to treat patients with a condition or disease. This study is open-label, which means that both participants and study doctors know which study treatment is given to participants Participants will be administered subcutaneous (SC) treatment of risankizumab every 12 weeks for up to 44 weeks or provided deucravacitinib oral tablets to be taken once daily. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting3 awards Phase 41 criteria
JNJ-77242113
for Plaque Psoriasis
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Recruiting1 award Phase 3
TLL018 Tablets
for Plaque Psoriasis
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of TLL018 as therapy in 120 participants with moderate-to-severe PP.
Recruiting0 awards Phase 27 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Premier Clinical Research?
Premier Clinical Research is a medical facility located in Spokane, Washington. This center is recognized for care of Psoriasis, Acne, Plaque Psoriasis, Atopic Dermatitis, Eczema and other specialties. Premier Clinical Research is involved with conducting 116 clinical trials across 66 conditions. There are 2 research doctors associated with this hospital, such as William Werschler and Philip Werschler.